Cargando…
Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care
According to the GLOBOCAN 2020, prostate cancer (PCa) is the most often diagnosed male cancer in 112 countries and the leading cancer-related death in 48 countries. Moreover, PCa incidence permanently increases in adolescents and young adults. Also, the rates of metastasising PCa continuously grow u...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263437/ https://www.ncbi.nlm.nih.gov/pubmed/35821883 http://dx.doi.org/10.1007/s13167-022-00288-z |
_version_ | 1784742737353900032 |
---|---|
author | Mazurakova, Alena Samec, Marek Koklesova, Lenka Biringer, Kamil Kudela, Erik Al-Ishaq, Raghad Khalid Pec, Martin Giordano, Frank A. Büsselberg, Dietrich Kubatka, Peter Golubnitschaja, Olga |
author_facet | Mazurakova, Alena Samec, Marek Koklesova, Lenka Biringer, Kamil Kudela, Erik Al-Ishaq, Raghad Khalid Pec, Martin Giordano, Frank A. Büsselberg, Dietrich Kubatka, Peter Golubnitschaja, Olga |
author_sort | Mazurakova, Alena |
collection | PubMed |
description | According to the GLOBOCAN 2020, prostate cancer (PCa) is the most often diagnosed male cancer in 112 countries and the leading cancer-related death in 48 countries. Moreover, PCa incidence permanently increases in adolescents and young adults. Also, the rates of metastasising PCa continuously grow up in young populations. Corresponding socio-economic burden is enormous: PCa treatment costs increase more rapidly than for any other cancer. In order to reverse current trends in exploding PCa cases and treatment costs, pragmatic decisions should be made, in favour of advanced populational screening programmes and effective anti-PCa protection at the level of the health-to-disease transition (sub-optimal health conditions) demonstrating the highest cost-efficacy of treatments. For doing this, the paradigm change from reactive treatments of the clinically manifested PCa to the predictive approach and personalised prevention is essential. Phytochemicals are associated with potent anti-cancer activity targeting each stage of carcinogenesis including cell apoptosis and proliferation, cancer invasiveness and metastatic disease. For example, their positive effects are demonstrated for stabilising and restoring mitochondrial health quality, which if compromised is strongly associated with sub-optimal health conditions and strong predisposition to aggressive PCa sub-types. Further, phytochemicals significantly enhance response of cancer cells to anti-cancer therapies including radio- and chemotherapy. Evident plant-based mitigation of negative side-effects frequently observed for conventional anti-cancer therapies has been reported. Finally, dual anti-cancer and anti-viral effects of phytochemicals such as these of silibinin have been demonstrated as being highly relevant for improved PCa management at the level of secondary and tertiary care, for example, under pandemic conditions, since PCa-affected individuals per evidence are highly vulnerable towards COVID-19 infection. Here, we present a comprehensive data analysis towards clinically relevant anti-cancer effects of phytochemicals to be considered for personalised anti-PCa protection in primary care as well as for an advanced disease management at the level of secondary and tertiary care in the framework of predictive, preventive and personalised medicine. |
format | Online Article Text |
id | pubmed-9263437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92634372022-07-08 Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care Mazurakova, Alena Samec, Marek Koklesova, Lenka Biringer, Kamil Kudela, Erik Al-Ishaq, Raghad Khalid Pec, Martin Giordano, Frank A. Büsselberg, Dietrich Kubatka, Peter Golubnitschaja, Olga EPMA J Review According to the GLOBOCAN 2020, prostate cancer (PCa) is the most often diagnosed male cancer in 112 countries and the leading cancer-related death in 48 countries. Moreover, PCa incidence permanently increases in adolescents and young adults. Also, the rates of metastasising PCa continuously grow up in young populations. Corresponding socio-economic burden is enormous: PCa treatment costs increase more rapidly than for any other cancer. In order to reverse current trends in exploding PCa cases and treatment costs, pragmatic decisions should be made, in favour of advanced populational screening programmes and effective anti-PCa protection at the level of the health-to-disease transition (sub-optimal health conditions) demonstrating the highest cost-efficacy of treatments. For doing this, the paradigm change from reactive treatments of the clinically manifested PCa to the predictive approach and personalised prevention is essential. Phytochemicals are associated with potent anti-cancer activity targeting each stage of carcinogenesis including cell apoptosis and proliferation, cancer invasiveness and metastatic disease. For example, their positive effects are demonstrated for stabilising and restoring mitochondrial health quality, which if compromised is strongly associated with sub-optimal health conditions and strong predisposition to aggressive PCa sub-types. Further, phytochemicals significantly enhance response of cancer cells to anti-cancer therapies including radio- and chemotherapy. Evident plant-based mitigation of negative side-effects frequently observed for conventional anti-cancer therapies has been reported. Finally, dual anti-cancer and anti-viral effects of phytochemicals such as these of silibinin have been demonstrated as being highly relevant for improved PCa management at the level of secondary and tertiary care, for example, under pandemic conditions, since PCa-affected individuals per evidence are highly vulnerable towards COVID-19 infection. Here, we present a comprehensive data analysis towards clinically relevant anti-cancer effects of phytochemicals to be considered for personalised anti-PCa protection in primary care as well as for an advanced disease management at the level of secondary and tertiary care in the framework of predictive, preventive and personalised medicine. Springer International Publishing 2022-07-08 /pmc/articles/PMC9263437/ /pubmed/35821883 http://dx.doi.org/10.1007/s13167-022-00288-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Mazurakova, Alena Samec, Marek Koklesova, Lenka Biringer, Kamil Kudela, Erik Al-Ishaq, Raghad Khalid Pec, Martin Giordano, Frank A. Büsselberg, Dietrich Kubatka, Peter Golubnitschaja, Olga Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care |
title | Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care |
title_full | Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care |
title_fullStr | Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care |
title_full_unstemmed | Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care |
title_short | Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care |
title_sort | anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine — comprehensive effects of phytochemicals in primary, secondary and tertiary care |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263437/ https://www.ncbi.nlm.nih.gov/pubmed/35821883 http://dx.doi.org/10.1007/s13167-022-00288-z |
work_keys_str_mv | AT mazurakovaalena antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT samecmarek antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT koklesovalenka antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT biringerkamil antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT kudelaerik antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT alishaqraghadkhalid antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT pecmartin antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT giordanofranka antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT busselbergdietrich antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT kubatkapeter antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare AT golubnitschajaolga antiprostatecancerprotectionandtherapyintheframeworkofpredictivepreventiveandpersonalisedmedicinecomprehensiveeffectsofphytochemicalsinprimarysecondaryandtertiarycare |